Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Konstantin Schlick"'
Autor:
Konstantin Schlick, Antonia Gantschnigg, Alexander Seymer, Florian Huemer, Richard Greil, Lukas Weiss
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 16997-17004 (2023)
Abstract Background Pancreatic cancer is mostly diagnosed in an advanced stage and treated with systemic therapy with palliative intent. Nowadays, the doublet chemotherapy of Gemcitabine and nab‐paclitaxel (Gem‐Nab) is one of the most frequently
Externí odkaz:
https://doaj.org/article/b9a49e1c5b3e43409a6abf40578766f3
Autor:
Florian Huemer, Celine Dunkl, Gabriel Rinnerthaler, Konstantin Schlick, Ronald Heregger, Klaus Emmanuel, Daniel Neureiter, Eckhard Klieser, Michael Deutschmann, Falk Roeder, Richard Greil, Lukas Weiss
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAge-standardized mortality rates for metastatic colorectal cancer (mCRC) are highest among elderly patients. In current clinical guidelines, treatment recommendations for this patient population are based on a limited number of clinical tri
Externí odkaz:
https://doaj.org/article/720d9644af5b483b82a00212c0f67223
Autor:
Dominik Andreas Barth, Carina Brenner, Jakob Michael Riedl, Felix Prinz, Eva Valentina Klocker, Konstantin Schlick, Peter Kornprat, Karoline Lackner, Herbert Stöger, Michael Stotz, Armin Gerger, Martin Pichler
Publikováno v:
Cancer Medicine, Vol 9, Iss 15, Pp 5473-5479 (2020)
Abstract Background The advanced lung cancer inflammation index (ALI) was first introduced for prognosis prediction in lung cancer patients and since then evaluated in several other malignancies. However, in pancreatic cancer (PC) the ALI and its pro
Externí odkaz:
https://doaj.org/article/28b62e9a84b64f2e8f8fed8ab915e556
Autor:
Moritz Müller, Florian Posch, Dominik Kiem, Dominik Barth, Lena Horvath, Michael Stotz, Renate Schaberl-Moser, Martin Pichler, Richard Greil, Philipp J. Jost, Andreas Seeber, Arno Amann, Konstantin Schlick, Armin Gerger, Jakob M. Riedl
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) ve
Externí odkaz:
https://doaj.org/article/051ef20ccbc94d37ab602098e3f67016
Autor:
Konstantin Schlick MD, Dominik Kiem MD, Florian Huemer MD, Daniel Neureiter MD, Lukas Weiss MD, Richard Greil MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Background: Pancreatic cancer carries a devastating prognosis and is the fourth leading cause for cancer-related death in the United States and most European countries. Although one-third of patients receive a palliative third line therapy, the benef
Externí odkaz:
https://doaj.org/article/d8eafaac4d1e4f2ba17edb931594a20b
Autor:
Konstantin Schlick, Florian Hohla, Frank Hamacher, Hubert Hackl, Clemens Hufnagl, Steiner Markus, Teresa Magnes, Simon Peter Gampenrieder, Thomas Melchardt, Stefan Stättner, Cornelia Hauser-Kronberger, Richard Greil, Gabriel Rinnerthaler
Publikováno v:
Future Science OA, Vol 7, Iss 2 (2021)
FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered
Externí odkaz:
https://doaj.org/article/36b61557ba3f4e51b32c0fc4e97473cb
Publikováno v:
Biomolecules, Vol 11, Iss 10, p 1469 (2021)
Pancreatic adenocarcinoma carries a devastating prognosis. For locally advanced and metastatic disease, several chemotherapeutic regimens are currently being used. Over the past years, novel approaches have included targeting EGFR, NTRK, PARP, K-Ras
Externí odkaz:
https://doaj.org/article/5048985886ec4236a8b1cf24dbcfcf59
Autor:
Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl-Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva-Maria Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova, Dietmar Geissler, Wolfgang R. Sperr, Sabine Hojas, Inga M. Rogulj, Johannes Andel, Richard Greil
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-16 (2016)
Abstract Background The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20–30 % bone marrow blasts (AML20–30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML.
Externí odkaz:
https://doaj.org/article/b40b7ac28a984159b4bb8b27ecd44658
Autor:
Konstantin Schlick, Teresa Magnes, Lukas Ratzinger, Bernhard Jaud, Lukas Weiss, Thomas Melchardt, Richard Greil, Alexander Egle
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0206688 (2018)
BACKGROUND:Despite modern chemotherapy regimens, survival of pancreatic cancer patients remains dismal. Toxicity is a major concern and it is a challenge to upfront identify patients with the highest benefit from aggressive polychemotherapy. We aimed
Externí odkaz:
https://doaj.org/article/83d6ca8a57a441dfa212aab0b29c14ff
Autor:
Slaven Pikija, Georg Pilz, Gerald Gschwandtner, Cornelia Rösler, Konstantin Schlick, Richard Greil, Johann Sellner
Publikováno v:
Frontiers in Neurology, Vol 7 (2016)
Acute central nervous system (CNS) toxicity and immune-related side effects are increasingly recognized with the use of monoclonal antibodies for cancer therapy. Here, we report a patient who developed of acute-onset encephalopathy and coma, which be
Externí odkaz:
https://doaj.org/article/76da051437f540db80132b3fbbb261d9